Anticancer titanium agents

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 6, 2001, Pages 969-979

  Caruso, F ^a   Rossi, M ^a   Pettinari, C ^a  

^a CNR   (Italy)

Author keywords

Cancer; Chemotherapy; Cytotoxicity; Liposomes; Metal compounds; Titanium (Ti); Tumour

Indexed keywords

ANTINEOPLASTIC AGENT; BUDOTITANE; CISPLATIN; DNA; LIPOSOME; PROPYLENE GLYCOL; PYRAZOLONE DERIVATIVE; TITANIUM DERIVATIVE; TITANOCENE; TITANOCENE DICHLORIDE; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; BIOACCUMULATION; BLADDER CARCINOMA; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DNA INTERACTION; DRUG EXCRETION; DRUG FORMULATION; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TRANSPORT; GASTROINTESTINAL TUMOR; HUMAN; HUMAN CELL; LUNG CANCER; MELANOMA; MOUSE; NEPHROTOXICITY; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0034965054     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.6.969     Document Type: Review

References (49)

1. Platinum compounds a new class of potent antitumour agents
2. Cisplatin and related drugs
3. Cellular responses to cisplatin
4. Crystal structure of the anticancer drug cisplatin bound to duplex DNA
5. Complexes other than platinum as antitumour agents
6. Non-platinum antitumour compounds
7. Anticancer metal complexes and tumour targeting strategies
8. Budotitane, a new tumor-inhibiting titanium compound in preclinical and clinical development
9. Metal β-Diketonates and Allied Derivatives
10. New tumor-inhibiting metal complexes
11. Antitumor activity of phenyl substituted dihalogenobis(1-phyenyl-1,3-butanedionato)titanium(IV) compounds
12. Tumor-inhibiting bis(β-diketonato)metal complexes. Budotitane, the first transition metal complex after platinum to qualify for clinical trials
13. Metal complexes with specific activity against colorectal tumors evaluation of a tumor model close to the clinical situation
14. Preclinical evaluation of dichlorobis(1-phenyl-1,3-butanedionato)titanium(IV) and budotitane
15. Clinical Phase I and pharmacokinetic trial of the new titanium complex budotitane
16. Transition and main-group metal cyclo-pentadienyl complexes preclinical studies on a series of antitumour agents of different structural type
17. Tumor inhibition by titanocene complexes. Activity against B16 melanoma and colon 38 carcinoma
18. Pattern of toxicity by titanocene dichloride in mice. Blood and urine chemical parameters
19. Titansalze in der (ortherapie)
20. Phase I evaluation of the new antineoplastic compound titanocene dichloride in adults with solid tumors
21. Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors
22. Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer
23. Organometallic titanium, vanadium, niobium, molybdenum and rhenium complexes - Early transition metal antitumour drugs
24. Abnormal trace metals in man titanium
25. The first specific Ti(IV)-protein complex potential relevance to anticancer activity of titanocenes
26. IV-transferrin by cancer cells understanding the mechanism of action of the anticancer drug titanocene
27. Formation of titanium(IV) transferrin by reaction of human serum apotransferrin with titanium complexes
28. Intracellular localization of titanium with xenografted sensitive human tumors after treatment with the antitumour agent titanocene dichloride
29. New platinum, titanium and ruthenium complexes with patterns of DNA damage in rat ovarian tumor cells
30. Antitumour metallocenes structure-activity studies and interactions with biomolecules
31. Anti-proliferative activity and mechanism of action of titanocene dichloride
32. 5-cyclopentadienyl) (theophyllinato)titanium(III)
33. 5-cyclopentadienyl) purinato titanium(IV), a model for the interaction of the antitumor titanocene dichloride molecule with DNA bases
34. 2Ti or DNA-CpTi adducts depending on pH
35. Antitumour-active bis-β-diketonato metal complexes budotitane - A new anticancer agent
36. Antitumor activity of titanocene amino acid complexes
37. Synthesis, structure and antitumor activity of a novel tetranuclear titanium complex
38. Liposomes as a controlled-release system
39. Crystal and molecular structure of cyclotetrakis[μ-oxo- (bis(2,2,6,6- dionato)titanium(IV)], pentane adduct
40. Presence of titanium and zinc in human leukocytes
41. Coordination compounds in medicinal chemistry
42. Crystal structure at 3.5Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor
43. Photokilling of T-24 human bladder cancer cells with titanium dioxide Molecules
44. Biochemical application of photoelectrochemistry killing of malignant cells with titanium dioxide powder
45. 2 nanoparticles damage to cellular membranes and genetic supramolecules
46. 2 particles on U937 cells
47. In vitro studies on the role of titanium in aseptic loosening
48. The in vitro response to particulate titanium alloy
49. 5, M = Ti, V, Zr. Aqueous kinetics, equilibria and mechanistic implication for a new class of antitumor agents